|
Persistent Systems launches new D2P automation solution
Mar 08, 2013 (Datamonitor via COMTEX) --
Persistent Systems, a provider of software product and technology services, has announced the availability of PaxPharma, a compliance-based, design to print, or D2P, automation solution designed specifically for pharmaceutical packaging and product lifecycle management, or PLM.
PaxPharma, the newest offering in the Paxpro Enterprise Collaboration Solution suite delivers the entire D2P supply chain on one easy to use platform - from NPI/NPD, product design and CAD, to labeling, artwork management, PLM and document lifecycle management for pharmacovigilance, the company said.
PaxPharma includes an FDA rules database module that manages the rules and regulations set by the FDA for each product type, from OTC drug to cosmetics. This module automatically selects several of the FDA rules based on product attributes specified by the labeling specialist - greatly reducing errors and providing significant time savings, the company added.
Near print-ready Drug Fact Templates (DFT's) and labeling documents can be produced using this module allowing marketing managers to have better control of their artwork and labeling assets while reducing dependency on graphic artists and post production iterations.
"PaxPharma delivers an enhanced user experience through a fully integrated solution with secure data transfer across modules that significantly helps reduce human error, ensure regulatory compliance, and improve time to market," said Ram Pazhayannur, VP of Paxpro Business Unit, Persistent Systems. "We are very excited to deliver this next generation compliance-based automation solution for the pharmaceutical industry that simplifies the entire D2P process across the supply chain - from brand managers, to suppliers and customers."
http://www.datamonitor.com
Republication or redistribution, including by framing or similar means,
is expressly prohibited without prior written consent. Datamonitor shall
not be liable for errors or delays in the content, or for any actions
taken in reliance thereon
[ Back To Technology News's Homepage ]
|